ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare ...( EXTON Pa. Oct. 31 /- ViroPharma I...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007
EXTON, Pa., Oct. 31 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Michel de Rosen, president and chief executive officer of ViroPharma, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at 8:50 A.M. ET on Tuesday, November 6, 2007. The conference is being held at the New York Palace Hotel.
ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com and available through November 20, 2007.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com.
'/>"/>
| SOURCE ViroPharma Incorporated Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. ViroPharma Announces Presentation of Additional HCV-796 Data at Meeting of The European Association for the Study of the Liver
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/3/2008)...KJAVIK, Iceland, Oct. 3 /- ...he filing of an investigational new drug,(IND) app...cule modulator,of phosphodiesterase 4 (PDE4), with...mpound is being developed as a new and potentially...ss and cognitive deficits associated,with Alzheime...
(Date:10/2/2008)...Study Will Compare the Results of Rosetta Genomics... Differentiates Squamous From non Squamous no...Methods, A Test Based on the miRview(TM) Technolog...bia University,s High Complexity Molecular Patholo..., Rosetta Genomics is Expecting to Launch miRview...
(Date:10/2/2008)...EBORG, Sweden, October 2 /- Calabar A...e study in xerostomia ("dry mouth"),patients has b...ied in 45,dry mouth patients between the ages of 2... dose for evaluation in a succeeding Phase III eff... cholinesterase inhibitor,physostigmine. It is adm...
(Date:10/2/2008)...ata Indicate Dual Modes of Action and Synergy with...ll/ -- Access Pharmaceuticals, Inc.,(OTC Bulletin ...ical,studies on Angiolix showing that by blocking ...effect as well as a direct anti-proliferative effe...human breast cancer (MX-1),Angiolix had a signifi...
Breaking Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3New Legislation Would Expedite Medicare Patient Access to Physical Therapy 16169 1New Legislation Would Expedite Medicare Patient Access to Physical Therapy 16169 2MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 1MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 2MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 3MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 4Too Little Sleep Leads to Too Much Weight for Kids 16166 1Too Little Sleep Leads to Too Much Weight for Kids 16166 2Too Little Sleep Leads to Too Much Weight for Kids 16166 3Too Little Sleep Leads to Too Much Weight for Kids 16166 4New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 1New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 2New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 3[0] deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders[0] Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay[0] Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients[0] Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
...h Concentrations Reached in Key Lung Compartments,...RNewswire-FirstCall/ -- Arpida Ltd. today announce... AR-709. These radiolabelled,Human Microdose studi... , This groundbreaking study is the first ever usi...ntrations in lung compartments.,The results showed...
...vey Shows 89% of Patients Prefer Orapred ODT Over ...e/ -- Alliant,Pharmaceuticals announced today surv...T(TM) (Prednisolone sodium phosphate,orally disint...esults of the patient feedback survey involving mo...70) of the children,preferred Orapred ODT over liq...
Other Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5Orapred ODT Tastes Good 2Orapred ODT Tastes Good 3(Date:10/6/2008)...recently posted detailed information on its Cimzia...ous side effects caused by the drug and its family...al side effects are the development of fatal infec...d child patients. , Denve...mber one resource for everything and anything lega...
(Date:10/6/2008)...f women suffer with symptoms of menopause as House...plan. But the effects of our current economic cris...singly difficult for U.S. women to cope with the c...s new cost effective drug-free guidelines to help ... , Las Vegas, NV (PRWEB) ...
(Date:10/6/2008)...fers up to 50 percent savings on medical services ... Belleville, Ill. (Vocus) October 6, 2008 -- Alls....allsup.com/Health-Discount-Program.aspx/?=PRJ2 [H...rogram] to help millions of people with disabiliti...l services. The program is among the new financial...
(Date:10/6/2008)...swire-FirstCall/ -- SAP AG (NYSE: SAP ),today ann...r vice president,of the Healthcare industry busine...8, Mr. Papandrea will help drive SAP,s industry le...olutions to healthcare,organizations around the wo... the 3rd annual Ambassadors Dinner and the U.S.-EU...
Breaking Medicine News(10 mins):Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 3Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3[0] LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis[0] Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines[0] Allsup Introduces Health Discount Program to Millions of People with Disabilities[0] SAP Appoints John Papandrea to Lead Healthcare Business Unit
...that suppresses the immune system may slow the pro...al trial of 10 people aged 8 to 35 years with type...fied antibody.// A 14-day course of the drug appea... insulin production commonly seen in type 1 diabet...
...emarkable for its ability to live in the strong ac...broccoli is powerful against the bacterium that is...r.// It's now well established that this microbe i...r. Clearing it with antibiotics is an important fo...
...d for facial cosmetic surgery has increased, so to...s never been more popular. Most products go down i...rs in Texas have looked at how cosmetic surgery, a...marketplace over the last decade. They surveyed 1...
... to acquire the cardiovascular stent business of B... in cash. Abbott said the deal will strengthen its...tional presence in the vascular business for polym...at keep blood vessels open.// Abbott has been the...
Other Medicine News:Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |